Skip to content
Home/Companies/Biotech/Code Biotherapeutics
Code Biotherapeutics

Code Biotherapeutics

Biotech·US·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Code Biotherapeutics?

Code Biotherapeutics is an American Biotech company, currently owned by 4Bio Partners since 2022.

Hand-verified · updated 2026-05-21

Open JSON · CC-BY
4Bio Partners
Investor
4Bio Partners
4BIO Ventures III · 2022 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusActive
Websitewww.codebiotx.com

More from 4BIO Ventures III

Other portfolio companies in the same fund.

Aptadir Therapeutics
Active
BiotechItaly· 2026
Cloverleaf Bio
Active
BiotechUnited States· 2026
Cytospire Therapeutics
Cytospire Therapeutics
Active
BiotechUK· 2026
Actithera
Actithera
Active
BiotechSwitzerland· 2025
Hornet Therapeutics
Active
BiotechUK· 2024
March Biosciences
March Biosciences
Active
BiotechUS· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Code Biotherapeutics?

Code Biotherapeutics is currently owned by 4Bio Partners, through 4BIO Ventures III, since 2022.

When did 4Bio Partners acquire Code Biotherapeutics?

4Bio Partners acquired Code Biotherapeutics in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue